MANISH SARAN: Open Payments
NPI 1821208224 · SHREVEPORT, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,195 in 122 payments from 16 companies in 2025. Trend: 2023 $1,804 · 2024 $2,095 · 2025 $2,195
Food & beverage: $2,195
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 28 | $479 |
| Neurocrine BioSciences, Inc. | 25 | $379 |
| Collegium Pharmaceutical, Inc. | 10 | $186 |
| Supernus Pharmaceuticals, Inc. | 8 | $186 |
| Teva Pharmaceuticals USA, Inc. | 8 | $146 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $133 |
| Lundbeck LLC | 5 | $118 |
| E.R. Squibb & Sons, L.L.C. | 5 | $101 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $91 |
| Vanda Pharmaceuticals Inc. | 5 | $84 |
Products named: INGREZZA, ARISTADA, Jornay PM, Qelbree, LYBALVI, REXULTI, AUSTEDO XR, CAPLYTA.
Industry payments across LA — which companies pay providers there.
